(MGTX) MeiraGTx Holdings - Ratings and Ratios
Gene Therapies, Retinal Diseases, Neurodegenerative Disorders, Xerostomia Treatment
MGTX EPS (Earnings per Share)
MGTX Revenue
Description: MGTX MeiraGTx Holdings October 23, 2025
MeiraGTx Holdings plc (NASDAQ:MGTX) is a U.S.–based, clinical-stage biotechnology firm that focuses on gene-therapy platforms for serious ocular, neurodegenerative, and xerostomia indications. Founded in 2015 and headquartered in New York, the company leverages adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to target tissues.
Its lead pipeline includes several Phase 2 programs: AAV-AQP1 for radiation-induced xerostomia (also being evaluated in Sjögren’s syndrome), AAV-GAD for Parkinson’s disease, AAV-RPE65 for RPE65-associated retinal dystrophy, and AAV-CNGB3/AAV-CNGA3 for achromatopsia. Preclinical assets span AAV-RDH12 (retinal dystrophy), AAV-BBS10 (Bardet-Biedl syndrome), AAV-RetGC (Leber congenital amaurosis type 1), and AAV-UPF1 (ALS), plus programs targeting Alzheimer’s disease and neovascular age-related macular degeneration.
Strategic collaborations amplify MeiraGTx’s development capacity: a joint venture with Johnson & Johnson Innovative Medicine advances inherited retinal disease gene therapies, while a partnership with Hologen Limited supports AAV-GAD for Parkinson’s, AAV-BDNF for genetic obesity, and broader CNS gene-medicine projects. These alliances provide both milestone funding and access to large-scale manufacturing capabilities.
From a financial perspective, MeiraGTx reported approximately $70 million of cash and short-term investments in its latest 10-Q (Q3 2024), giving it roughly a 12-month runway at current burn rates, and its R&D expense grew ~15 % YoY, reflecting the escalation of Phase 2 trial activity. The global gene-therapy market is projected to reach $13 billion by 2029 (CAGR ≈ 19 %), driven by regulatory approvals and expanding payer coverage-key macro drivers that could materially affect MeiraGTx’s valuation.
For a data-driven deep-dive into MeiraGTx’s risk-adjusted upside and comparable peer metrics, see the detailed analysis on ValueRay.
MGTX Stock Overview
| Market Cap in USD | 690m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2018-06-08 |
MGTX Stock Ratings
| Growth Rating | 26.4% |
| Fundamental | 27.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 14.1% |
| Analyst Rating | 4.60 of 5 |
MGTX Dividends
Currently no dividends paidMGTX Growth Ratios
| Growth Correlation 3m | 67.9% |
| Growth Correlation 12m | 64.6% |
| Growth Correlation 5y | -69.5% |
| CAGR 5y | 9.45% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.16 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.34 |
| Sharpe Ratio 12m | 0.44 |
| Alpha | 16.91 |
| Beta | 1.384 |
| Volatility | 60.28% |
| Current Volume | 292.6k |
| Average Volume 20d | 318.7k |
| Stop Loss | 7.8 (-7.3%) |
| Signal | -0.08 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-157.5m TTM) > 0 and > 6% of Revenue (6% = 2.28m TTM) |
| FCFTA -0.67 (>2.0%) and ΔFCFTA -28.13pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -16.75% (prev 785.1%; Δ -801.9pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.65 (>3.0%) and CFO -129.1m > Net Income -157.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 0.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (80.6m) change vs 12m ago 25.18% (target <= -2.0% for YES) |
| Gross Margin 26.56% (prev -70.99%; Δ 97.56pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 16.30% (prev 3.05%; Δ 13.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -11.26 (EBITDA TTM -132.2m / Interest Expense TTM 12.8m) >= 6 (WARN >= 3) |
Altman Z'' -21.43
| (A) -0.03 = (Total Current Assets 47.1m - Total Current Liabilities 53.4m) / Total Assets 198.7m |
| (B) -3.93 = Retained Earnings (Balance) -780.8m / Total Assets 198.7m |
| warn (B) unusual magnitude: -3.93 — check mapping/units |
| (C) -0.62 = EBIT TTM -144.7m / Avg Total Assets 232.7m |
| (D) -4.03 = Book Value of Equity -788.3m / Total Liabilities 195.8m |
| Total Rating: -21.43 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.23
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -18.14% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 27.19 = -2.50 |
| 5. Debt/Ebitda -0.37 = -2.50 |
| 6. ROIC - WACC (= -102.8)% = -12.50 |
| 7. RoE -315.6% = -2.50 |
| 8. Rev. Trend 34.46% = 2.58 |
| 9. EPS Trend 52.96% = 2.65 |
What is the price of MGTX shares?
Over the past week, the price has changed by -3.67%, over one month by +0.00%, over three months by +5.79% and over the past year by +31.00%.
Is MeiraGTx Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MGTX is around 7.72 USD . This means that MGTX is currently overvalued and has a potential downside of -8.2%.
Is MGTX a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MGTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 27.6 | 227.8% |
| Analysts Target Price | 27.6 | 227.8% |
| ValueRay Target Price | 8.7 | 3.8% |
MGTX Fundamental Data Overview November 07, 2025
P/E Forward = 1.6147
P/S = 18.204
P/B = 228.2969
Beta = 1.384
Revenue TTM = 37.9m USD
EBIT TTM = -144.7m USD
EBITDA TTM = -132.2m USD
Long Term Debt = 73.8m USD (from longTermDebt, last quarter)
Short Term Debt = 2.65m USD (from shortTermDebt, last quarter)
Debt = 80.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 48.3m USD (from netDebt column, last quarter)
Enterprise Value = 738.5m USD (690.2m + Debt 80.5m - CCE 32.2m)
Interest Coverage Ratio = -11.26 (Ebit TTM -144.7m / Interest Expense TTM 12.8m)
FCF Yield = -18.14% (FCF TTM -134.0m / Enterprise Value 738.5m)
FCF Margin = -353.3% (FCF TTM -134.0m / Revenue TTM 37.9m)
Net Margin = -415.4% (Net Income TTM -157.5m / Revenue TTM 37.9m)
Gross Margin = 26.56% ((Revenue TTM 37.9m - Cost of Revenue TTM 27.8m) / Revenue TTM)
Gross Margin QoQ = 27.50% (prev 28.45%)
Tobins Q-Ratio = 3.72 (Enterprise Value 738.5m / Total Assets 198.7m)
Interest Expense / Debt = 3.77% (Interest Expense 3.03m / Debt 80.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -114.3m (EBIT -144.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.88 (Total Current Assets 47.1m / Total Current Liabilities 53.4m)
Debt / Equity = 27.19 (Debt 80.5m / totalStockholderEquity, last quarter 2.96m)
Debt / EBITDA = -0.37 (negative EBITDA) (Net Debt 48.3m / EBITDA -132.2m)
Debt / FCF = -0.36 (negative FCF - burning cash) (Net Debt 48.3m / FCF TTM -134.0m)
Total Stockholder Equity = 49.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -79.26% (Net Income -157.5m / Total Assets 198.7m)
RoE = -315.6% (Net Income TTM -157.5m / Total Stockholder Equity 49.9m)
RoCE = -117.0% (out of range, set to none) (EBIT -144.7m / Capital Employed (Equity 49.9m + L.T.Debt 73.8m))
RoIC = -92.71% (negative operating profit) (NOPAT -114.3m / Invested Capital 123.3m)
WACC = 10.14% (E(690.2m)/V(770.7m) * Re(10.97%) + D(80.5m)/V(770.7m) * Rd(3.77%) * (1-Tc(0.21)))
Discount Rate = 10.97% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.56%
Fair Price DCF = unknown (Cash Flow -134.0m)
EPS Correlation: 52.96 | EPS CAGR: 62.96% | SUE: 2.66 | # QB: 1
Revenue Correlation: 34.46 | Revenue CAGR: -9.22% | SUE: -0.20 | # QB: 0
Additional Sources for MGTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle